Журнал кардиореспираторных исследований 2026. №2/1

Тема статьи

Surunkali buyrak kasalligida kardiovaskulyar xavfni baholash: klinik va prognostik yondashuv (50-53)

Авторы

G.X. Karabaeva, A.E. Xolbayev

Учреждение

Samarqand davlat tibbiyot universiteti

Аннотация

Surunkali buyrak kasalligi (SBK) yurak-qon tomir kasalliklari bilan chambarchas bog'liq bo'lib, bemorlarda mortalitetning asosiy sabablaridan biri hisoblanadi. Ushbu tadqiqotda SBK bemorlarida (n=100, 2–5-bosqich) kardiovaskulyar xavfni baholashda eGFR, global longitudinal strain (GLS), arterial gipertenziya va yallig'lanish markerlari (CRP) ning klinik-prognostik ahamiyati o'rganildi. Kesimli (cross-sectional) dizayndagi tadqiqot natijalariga ko'ra, eGFR pasayishi (41.6 ± 18.2 ml/min/1.73m²) va GLS buzilishi (−12.8 ± 3.1%) yurak-qon tomir xavfining oshishi bilan ishonchli bog'liq ekanligi aniqlandi. LVEF normal bo'lgan bemorlarda ham subklinik yurak disfunksiyasining mavjudligi GLSning erta diagnostik ahamiyatini tasdiqlaydi. Olingan natijalar eGFR, GLS va CRP ko'rsatkichlarini kompleks baholashning SBK bemorlarida kardiovaskulyar xavfni erta aniqlash va prognoz qilishda muhim o'rin tutishini ko'rsatadi.

Ключевые слова

surunkali buyrak kasalligi, kardiovaskulyar xavf, eGFR, global longitudinal strain, arterial gipertenziya, yurak disfunksiyasi, C- reaktiv oqsil.

Литературы

1. Levey, A. S., & Coresh, J. (2020). Chronic kidney disease. Lancet, 395(10225), 709–733. https://doi.org/10.1016/S0140- 6736(19)32596-5 2. KDIGO. (2021). Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements, 11(1), 1–169. 3. Foley, R. N., Parfrey, P. S., & Sarnak, M. J. (1998). Clinical epidemiology of cardiovascular disease in chronic kidney disease. American Journal of Kidney Diseases, 32(5 Suppl. 3), S112–S119. 4. London, G. M. (2018). Arterial stiffness in chronic kidney disease and end-stage renal disease. Nephrology Dialysis Transplantation, 33(3), 362–369. https://doi.org/10.1093/ndt/gfx236 5. Burnier, M., & Damianaki, A. (2023). Hypertension as cardiovascular risk factor in chronic kidney disease. Circulation Research, 132(8), 1050–1063. https://doi.org/10.1161/CIRCRESAHA.122.321762 6. Baaten, C. C. F. M. J., et al. (2023). Endothelial dysfunction in patients with chronic kidney disease. Journal of the American Society of Nephrology, 34(3), 387–400. 7. Duru, O. K., et al. (2025). Coordinated care for patients with chronic kidney disease. JAMA, 333(4), 310–320. 8. Braunwald, E. (2015). Heart failure. JACC: Heart Failure, 1(1), 1–20. https://doi.org/10.1016/j.jchf.2012.10.002 9. Patel, K. P., & Bhaskaran, M. (2014). Cardiorenal syndrome: Pathophysiology and treatment. Clinical Journal of the American Society of Nephrology, 9(4), 753–762. https://doi.org/10.2215/CJN.04680413 10. Kumar, M., et al. (2024). Global longitudinal strain in patients with chronic kidney disease. European Heart Journal — Cardiovascular Imaging, 25(2), 145–154. 11. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C. Y. (2004). Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine, 351(13), 1296–1305. https://doi.org/10.1056/NEJMoa041031 12. Matsushita, K., van der Velde, M., Astor, B. C., Woodward, M., Levey, A. S., de Jong, P. E., Coresh, J., & Gansevoort, R. T. (2010). Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality. Lancet, 375(9731), 2073–2081. https://doi.org/10.1016/S0140-6736(10)60674-5 13. Zoccali, C., Vanholder, R., Massy, Z. A., Ortiz, A., Sarafidis, P., Dekker, F. W., & Fliser, D. (2017). The systemic nature of CKD. Nature Reviews Nephrology, 13(6), 344–358. https://doi.org/10.1038/nrneph.2017.52 14. Stenvinkel, P. (2001). Inflammation in end-stage renal disease: The hidden enemy. Nephrology, 6(2), 57–68. 15. Ridker, P. M. (2003). Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 107(3), 363–369. https://doi.org/10.1161/01.CIR.0000053730.47739.3C 16. Townsend, R. R. (2015). Vascular stiffness in chronic kidney disease: Cause and consequence. Hypertension, 65(6), 1229– 1230. https://doi.org/10.1161/HYPERTENSIONAHA.115.05022 17. Wang, A. Y. M., & Lam, C. W. K. (2010). The cardiorenal syndrome in patients with chronic kidney disease. Journal of the American College of Cardiology, 56(3), 179–186. 18. McCullough, P. A. (2002). Cardiorenal risk: An important clinical intersection. Reviews in Cardiovascular Medicine, 3(2), 71– 76. 19. Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013). Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet, 382(9889), 339–352. https://doi.org/10.1016/S0140-6736(13)60595-4 20. Glassock, R. J., Warnock, D. G., & Delanaye, P. (2017). The global burden of chronic kidney disease: Estimates, variability and pitfalls. Nature Reviews Nephrology, 13(2), 104–114. https://doi.org/10.1038/nrneph.2016.163 21. Parfrey, P. S., & Foley, R. N. (1999). The clinical epidemiology of cardiac disease in chronic renal failure. Journal of the American Society of Nephrology, 10(7), 1606–1615. 22. Stevens, P. E., & Levin, A. (2013). Evaluation and management of chronic kidney disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline. Annals of Internal Medicine, 158(11), 825–830. https://doi.org/10.7326/0003-4819-158-11-201306040-00007 23. Cao, W., Zheng, D., & Tang, S. (2023). Cardiorenal syndrome and multi-organ interaction. Signal Transduction and Targeted Therapy, 8(1), 116. 24. European Renal Association. (2023). CKD and cardiovascular risk: A clinical review. ERA Clinical Practice Update. 25. Writing Group of the American Heart Association. (2021). Cardiovascular complications in chronic kidney disease. Circulation, 143(9), e200–e210. 26. Schiffrin, E. L., Lipman, M. L., & Mann, J. F. E. (2007). Chronic kidney disease: Effects on the cardiovascular system. Circulation, 116(1), 85–97. https://doi.org/10.1161/CIRCULATIONAHA.106.678342 27. Kooman, J. P., Dekker, M. J., Usvyat, L. A., Kotanko, P., van der Sande, F. M., Schober-Halstenberg, H. J., Finkelstein, F. O., & Levin, N. W. (2014). Inflammation and outcome in renal replacement therapy. Clinical Kidney Journal, 7(6), 516–522. https://doi.org/10.1093/ckj/sfu104 28. Levin, A. (2003). Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge. Kidney International Supplements, 64(Suppl. 87), S35–S38. 29. House, A. A., Wanner, C., Sarnak, M. J., Piña, I. L., McIntyre, C. W., Komenda, P., & Ix, J. H. (2019). Heart failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 95(6), 1304–1317. https://doi.org/10.1016/j.kint.2019.02.022 30. Herzog, C. A., Asinger, R. W., & Berger, A. K. (2011). Cardiovascular disease in chronic kidney disease. Lancet, 378(9800), 1428–1437. https://doi.org/10.1016/S0140-6736(11)60643-6